Copyright
©The Author(s) 2021.
World J Clin Cases. Dec 16, 2021; 9(35): 10979-10993
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10979
Published online Dec 16, 2021. doi: 10.12998/wjcc.v9.i35.10979
Table 1 Study information and patient characteristics of this Meta-analysis
Ref. | Design | Country | Period of enrolment | Groups | Number of patients | Age (yr) | Sex (male/female) | Obstruction levels | Causes of MOJ |
Chen et al[25], 2012 | Single-centre, RCT | China | Mar. 2009-Jan. 2010 | 125I + stent | 17 | 61.2 ± 14.5 | 12/5 | Hilar and distal | Cholangiocarcinoma (n = 7), hepatocellular carcinoma (n = 2), pancreatic cancer (n = 3), hepatic metastases from the stomach or colorectum (n = 5) |
Stent | 17 | 63.9 ± 9.3 | 10/7 | Cholangiocarcinoma (n = 6), hepatocellular carcinoma (n = 4), pancreatic cancer (n = 3), hepatic metastases from the stomach or colorectum (n = 4) | |||||
Hasimu et al[13], 2017 | Single-centre, RCT | China | July 2011-June 2014 | 125I + stent | 28 | 70.93 ± 8.58 | 11/17 | Hilar and distal | Cholangiocarcinoma (n = 48), gallbladder cancer (n = 7) |
Stent | 27 | 70.26 ± 9.71 | 14/13 | ||||||
Chen et al[26], 2018 | Single-centre, RCT | China | Sep. 2014-Nov. 2016 | 125I + stent | 13 | 66 (49, 88) | 8/5 | Lower | Pancreatic head carcinoma (n = 7), gallbladder carcinoma (n = 4), bile duct carcinoma (n = 2) |
Stent | 19 | 68 (48, 86) | 12/7 | Pancreatic head carcinoma (n = 11), bile duct carcinoma (n = 5), gallbladder carcinoma (n = 2), ampullary carcinoma (n = 1) | |||||
Jiao et al[14], 2017 | Single-centre, RCT | China | Jan. 2013- Jan. 2015 | 125I + stent | 31 | 60.4 ± 8.8 | 12/17 | Hilar and distal | Primary adenocarcinoma (n = 19), metastatic adenocarcinoma (n = 12) |
Stent | 30 | 60.2 ± 8.1 | 16/14 | Primary adenocarcinoma (n = 21), metastatic adenocarcinoma (n = 9) | |||||
Zhu et al[20], 2012 | Single-centre, RCT | China | Nov. 2008-Oct. 2010 | 125I + stent | 12 | 62.5 ± 21.0 | 7/5 | Hilar and distal | Primary adenocarcinoma (n = 8), metastatic adenocarcinoma (n = 4) |
Stent | 11 | 71.0 ± 22.0 | 9/2 | Primary adenocarcinoma (n = 5), metastatic adenocarcinoma (n = 6) | |||||
Zhu et al[21], 2018 | Multicentre, RCT | China | Oct. 2013-Mar. 2016 | 125I + stent | 164 | 65.0 (56.0, 75.0) | 103/61 | Hilar and distal | Biliary tract cancer (n = 80), pancreatic carcinoma (n = 46), lymph node metastases (n = 38) |
Stent | 164 | 64.0 (57.0, 75.0) | 109/55 | Biliary tract cancer (n = 74), pancreatic carcinoma (n = 53), lymph node metastases (n = 37) | |||||
Pan et al[15], 2020 | Retrospective cohort study | China | Mar. 2014-Dec. 2017 | 125I + stent | 30 | 56.53 ± 12.24 | 23/7 | Hilar and distal | NR |
Stent | 54 | 60.44 ± 11.83 | 35/19 | ||||||
Wang et al[24], 2017 | Retrospective cohort study | China | Sep. 2010-Feb. 2013 | 125I + stent | 24 | 57.3 (41, 80) | 29/21 | Hilar and distal | Holangiocarcinoma (n = 18), pancreatic head carcinoma (n = 14), hilar lymph node metastasis (n = 12), ampullary carcinoma (n = 6) |
Stent | 26 | ||||||||
Zhou et al[22], 2019 | Retrospective cohort study | China | Nov. 2015-Oct. 2017 | 125I + stent | 45 | 61.7 (32, 87) | 31/14 | Hilar, middle and distal | Cholangiocarcinoma (n = 18), gallbladder carcinoma (n = 6), pancreatic carcinoma (n = 4), hepatocellular carcinoma (n = 7), gastric cancer (n = 7), ampullary cancer (n = 0), hilar node metastases from other solid malignancies (n = 3) |
Stent | 87 | 64.4 (35, 92) | 59/28 | Cholangiocarcinoma (n = 32), gallbladder carcinoma (n = 9), pancreatic carcinoma (n = 17), hepatocellular carcinoma (n = 9), gastric cancer (n = 11), ampullary cancer (n = 1), hilar node metastases from other solid malignancies (n = 8) | |||||
Zhou et al[23], 2020 | Retrospectively cohort study | China | Jan. 2017-June 2018 | 125I + stent | 40 | 70.2 ± 13.8 | 21/19 | Hilar | Cholangiocarcinoma (n = 22), pancreatic cancer (n = 10), gallbladder cancer (n = 2), duodenal cancer (n = 2), metastatic cancer (n = 4) |
stent | 36 | 68.1 ± 12.2 | 21/15 | Cholangiocarcinoma (n = 19), pancreatic cancer (n = 8), gallbladder cancer (n = 3), duodenal cancer (n = 1), metastatic cancer (n = 5) |
- Citation: Chen WY, Kong CL, Meng MM, Chen WQ, Zheng LY, Mao JT, Fang SJ, Chen L, Shu GF, Yang Y, Weng QY, Chen MJ, Xu M, Ji JS. Percutaneous biliary stent combined with brachytherapy using 125I seeds for treatment of unresectable malignant obstructive jaundice: A meta-analysis. World J Clin Cases 2021; 9(35): 10979-10993
- URL: https://www.wjgnet.com/2307-8960/full/v9/i35/10979.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i35.10979